Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
Iyas Daghlas, Vascular Neurology Fellow and Stroke Researcher at the University of California, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Excited to share our new publication in Neurology: ‘Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.’
Cerebral venous thrombosis (CVT) is a rare form of stroke treated with anticoagulation.
Despite widespread off-label direct oral anticoagulant (DOAC) use, no adequately powered RCT has demonstrated DOAC efficacy, and many patients continue to be treated with warfarin, which carries substantial major bleeding risk.
We addressed this evidence gap by examining effects of naturally randomized genetic variants perturbing the protein targets of established (F2+F10) and emerging (F11) DOACs.
See Table 1 for a cool demonstration of the natural allocation of covariates/confounders across genotypes, mimicking an RCT ‘Table 1.’
We found evidence that genetically reduced levels of thrombin, factor Xa, and factor XI are associated with reduced CVT risk – see forest plot!
What this means:
- FXI inhibitors (milvexian, asundexian, etc) are among the most actively investigated therapeutic targets in thrombosis today, with multiple Phase III trials underway. Our data provide the first human genetic evidence supporting repurposing potential for CVT, a new indication for this drug class.
- Human genetics supports efficacy for established DOAC protein targets (thrombin and factor Xa) in reducing CVT risk
- These data support the notion that, in general, therapeutics that are effective for venous thromboembolism will likely also work for CVT
Appreciate collaborators Marta Pérez Alcántara and Dipender Gill!”
Title: Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis. A Mendelian Randomization Study
Authors: Iyas Daghlas, Marta Pérez Alcántara, Dipender Gill
Read the Full Article on Neurology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 04:43Ifeanyichukwu Ifechidere: The Critical Role of Calibrator Specificity in Anticoagulation Monitoring
-
Apr 22, 2026, 04:13Ilenia Calcaterra: Clinical Relevance of Persistent Pain in Emicizumab-Treated Haemophilia A
-
Apr 22, 2026, 03:56Annette Bowyer: Reflecting on Progress and Leadership in Laboratory Sciences
-
Apr 21, 2026, 21:07Tareq Abadl: Not Every Low Platelet Count Is True – Check the Smear First
-
Apr 21, 2026, 21:05Beverley Hunt: Honored to Receive the Lifetime Achievement Award at BSH 2026
-
Apr 21, 2026, 21:03Toong Youttananukorn: Proud to Support Data That Drives Action at WFH 2026
-
Apr 21, 2026, 20:48Ney Carter Borges: Endothelial Senescence as a Central Driver of Adipose Dysfunction in Heart Failure and Type 2 Diabetes
-
Apr 21, 2026, 20:29Can Stem Cell-Delivered Platelets Fight Drug-Resistant Bacteria?- RPTH Journal
-
Apr 21, 2026, 18:51WHO Expert Lorenzo Moja Discusses How Essential Medicines Policy Expands Access to Treatment – WFH